Skip to Main Content
our new site.
NLM Technical Bulletin
Full Text View
No Study Results Posted
Dose Escalation Study of Liposomal Paclitaxel Plus Capecitabine in Chinese Patients With Advanced Gastric Carcinoma
The recruitment status of this study is unknown because the information has not been verified recently.
Verified April 2009
by Nanjing Sike Pharmaceutical Co., Ltd..
Recruitment status was Active, not recruiting
Study NCT00881816 Information provided by Nanjing Sike Pharmaceutical Co., Ltd.
First Received on April 14, 2009. No Changes Posted
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Advanced Gastric Carcinoma
Additional conditions recognized in this trial
More general conditions related to this trial
Digestive System Diseases
Digestive System Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial
Additional drug interventions recognized in this trial
More general drug interventions related to this trial
Antineoplastic Agents, Phytogenic
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Sponsors listed in this trial
Nanjing Sike Pharmaceutical Co., Ltd.
Back to top of Main Content
Contact Help Desk
Lister Hill National Center for Biomedical Communications
U.S. National Library of Medicine
U.S. National Institutes of Health
U.S. Department of Health & Human Services
Freedom of Information Act
Links to all studies - primarily for crawlers